Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

Motzer, Robert J.; Alekseev, B. Ya.; Rha, Sun Young; Porta, Camillo; Eto, Masatoshi; Schmid, Peter; Grünwald, Viktor; Hutson, Thomas E.; Kopyltsov, Evgeny; Mendez-Vidal, María José; Kozlov, Vadim; Alyasova, Anna; Hong, Sung Hoo; Kapoor, Anil; Gordoa, Teresa Alonso; Merchan, Jaime R.; Winquist, Eric; Maroto, Pablo; Goh, Jeffrey C.; Kim, Miso; Gurney, Howard; Patel, Vijay; Peer, Avivit; Procopio, Giuseppe; Takagi, Toshio; Melichar, Bohuslav; Rolland, Frédéric; Giorgi, Ugo De; Wong, Shirley; Bedke, Jens; Schmidinger, Manuela; Dutcus, Corina E.; Smith, Alan D.; Dutta, Lea; Mody, Kalgi; Perini, Rodolfo F.; Xing, Dongyuan; Choueiri, Toni K.

doi:10.1056/nejmoa2035716

Cited by 1,214 publications

(1,184 citation statements)

References 18 publications

Supporting

Mentioning

1,076

Contrasting

Unclassified

Order By: Relevance

“…The Phase 3 CLEAR trial compared the combination to the then standard-of-care sunitinib (Pfizer). 10 The experimental cohort reported a median progressionfree survival of 2 years, compared to 9 months in the control group. The most common adverse events included hypertension and diarrhea.…”

Section: Pembrolizumab Combination Therapy Extends Lives Of Kidney Camentioning

confidence: 97%

Human vaccines & immunotherapeutics: news

2021

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Section: Pembrolizumab Combination Therapy Extends Lives Of Kidney Camentioning

confidence: 97%

Human vaccines & immunotherapeutics: news

2021

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

“…Immunotherapy has represented a breakthrough therapy for many cancer subtypes in the last years. Among genitourinary (GU) neoplasms, the urothelial carcinoma (UC) and the renal cell carcinoma (RCC) have benefitted mainly from immune checkpoint inhibitors (ICIs) both as single agents and in combination with other ICIs or tyrosine kinase inhibitors (TKIs) [1][2][3][4][5][6][7][8][9][10][11][12][13]. However, in prostate cancer (PCa), ICIs have shown limited efficacy primarily due to an immunologically 'cold' and immunosuppressive tumor microenvironment (TME) [15][16][17][18].…”

Section: Introductionmentioning

confidence: 99%

Cancer Vaccines for Genitourinary Tumors: Recent Progresses and Future Possibilities

Maiorano¹,

Schinzari²,

Ciardiello³

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: In the last years, many new treatment options have widened the therapeutic scenario of genitourinary malignancies. Immunotherapy has shown efficacy, especially in the urothelial and renal cell carcinomas, with no particular relevance in prostate cancer. However, despite the use of immune checkpoint inhibitors, there is still high morbidity and mortality among these neo-plasms. Cancer vaccines represent another way to activate the immune system. We sought to summarize the most recent advances in vaccine therapy for genitourinary malignancies with this review. Methods: We searched Pubmed, Embase and Cochrane Database for clinical trials conducted in the last ten years, focusing on cancer vaccines in the prostate, urothelial and renal cancer. Results: Various therapeutic vaccines, including DNA-based, RNA-based, peptide-based, dendritic cells, viral vectors, and modified tumor cells, have been demonstrated to induce specific immune responses in a variable percentage of patients. However, these responses rarely corresponded to significant survival improvements. Conclusions: Further pre-clinical and clinical studies will improve the knowledge about cancer vaccines in genitourinary malignancies to optimize dosage, select targets with a driver role for tumor development and growth, and finally overcome resistance mechanisms. Combination strategies represent possibly more effective and long-lasting treatments.

show abstract

“…Furthermore, combinations of ICIs with TT or other ICIs have led to a "doublet era" for mRCC treatment. The Keynote-426, JAVELIN Renal 101, IMmotion151, CheckMate-9ER, and CLEAR trials have investigated the effect of ICI plus TT combinations versus sunitinib in upfront therapy for mRCC [2,3].…”

mentioning

confidence: 99%

“…Because of these high CN rates, the old question of the role of CN has risen again in the doublet era and there is no answer to date. In this context, we conducted a meta-analysis of the IMmotion151, JAVELIN Renal 101, CheckMate-9ER, CheckMate-214, and CLEAR trials to find an answer [2,[5][6][7][8]. We did not include Keynote-426 because of a lack of CN results [4].…”

mentioning

confidence: 99%

“…e u r o p e a n u r o l o g y . c o m Forest plots of the HRs for (A) overall survival and (B) progression-free survival for groups with and without nephrectomy in trails investigating combination therapies in metastatic renal cell carcinoma[2,[5][6][7][8]. HR = hazard ratio; SE = standard error; IV = inverse variance; CI = confidence interval; df = degrees of freedom IO = immuno-oncology therapy.…”

mentioning

confidence: 99%

See 1 more Smart Citation